Skip to content
OpenCapital
Get started

Citius Oncology, Inc. CTOR Q3 2025 earnings

Reported August 12, 2025 · Before market open

Diluted EPS-$0.08Beat by $0.07
EPS estimate-$0.15

Next report

Aug 18, 2026 (in a month)
Revenue estimate$5.8M
EPS estimate-$0.04

Financials

Q3 2025

Income statement

See full
Operating income-$4.9M-6.8%
Net income-$5.4M-12.5%
EPS (diluted)-$0.08-14.3%

Balance sheet

See full
Cash & equivalents$112.0-57.1%
Total equity$32.4M+90.2%
Total assets$91.7M+86.4%

Cash flow

See full
Operating cash flow-$1.4M-4,447%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$190.33M—

Returns & leverage

See full
Return on equity-107.5%—
Current ratio0.3×+0.3×

Versus estimates

Revenue

Q2 2026$1.7MMiss by $5.3MQ1 2026$3.9MMiss by $428.9K

Diluted EPS

Q2 2026-$0.27Miss by $0.26Q1 2026-$0.06Miss by $0.02Q4 2025-$0.06In line
Q3 2025-$0.08Beat by $0.07
Q1 2025-$0.11Miss by $0.02Q4 2024-$0.09Miss by $0.03

Ask the moment Citius Oncology, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Citius Oncology, Inc. report Q3 2025 earnings?
Citius Oncology, Inc. (CTOR) reported Q3 2025 earnings on August 12, 2025 before market open.
What were Citius Oncology, Inc.'s Q3 2025 revenue and EPS?
Citius Oncology, Inc. reported diluted EPS of $-0.08 for Q3 2025.
Did Citius Oncology, Inc. beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.15 by $0.07.
How did Citius Oncology, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS declined 11.5% from $-0.07.
Where can I find Citius Oncology, Inc.'s Q3 2025 SEC filings?
You can read the 10-Q periodic report (0001213900-25-074992) directly on SEC EDGAR. The filing index links above go to sec.gov.